DK194783A - Fremgangsmaade til fremstilling af bicycliske forbindelser - Google Patents

Fremgangsmaade til fremstilling af bicycliske forbindelser Download PDF

Info

Publication number
DK194783A
DK194783A DK194783A DK194783A DK194783A DK 194783 A DK194783 A DK 194783A DK 194783 A DK194783 A DK 194783A DK 194783 A DK194783 A DK 194783A DK 194783 A DK194783 A DK 194783A
Authority
DK
Denmark
Prior art keywords
bicyclic
relations
procedure
preparation
represent
Prior art date
Application number
DK194783A
Other languages
English (en)
Other versions
DK160612B (da
DK194783D0 (da
DK160612C (da
Inventor
Michael Richard Attwood
Cedric Herbert Hassall
Robert Wilson Lambert
Geoffrey Lawton
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DK194783D0 publication Critical patent/DK194783D0/da
Publication of DK194783A publication Critical patent/DK194783A/da
Publication of DK160612B publication Critical patent/DK160612B/da
Application granted granted Critical
Publication of DK160612C publication Critical patent/DK160612C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/409—Compounds containing the structure P(=X)-X-acyl, P(=X) -X-heteroatom, P(=X)-X-CN (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Description

Figure DK194783AD00021
3 4 R betegner carboxyl, alkoxycarbonyl eller aralkoxycarbonyl, R og 5 4 5 R hver betegner hydrogen, eller R og R tilsammen betegner oxo, 6 7 6
R og R* hver betegner hydrogen eller alkyl eller aralkyl, eller R og R^ sammen med det nitrogenatom, hvortil de er bundet, betegner en 5- eller 6-leddet heteromonocyclisk ring, som kan indeholde et yderligere nitrogenatom eller et oxygen- eller svovlatom, og n betegner 0, 1 eller 2, og farmaceutisk acceptable salte deraf har anti-hypertensiv virkning og kan anvendes som medikamenter i form af farmaceutiske præparater.
Forbindelserne I fremstilles ved en række forskellige fremgangsmåder, og hidtil ukendte mellemprodukter til anvendelse dertil er forbindelser II, IV, XV og XVIla
Figure DK194783AD00022
II
IV
XV
Figure DK194783AD00031
XVIIa g hvor Hal betegner et halogenatom, og R betegner en phthaloylamino-gruppe.
DK194783A 1982-05-12 1983-05-02 Analogifremgangsmaade til fremstilling af ved begge n-atomer cyclopenta-, cyclohexa- og cyclohepta-annelerede pyrazol- og pyridazinderivater DK160612C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8213850 1982-05-12
GB8213850 1982-05-12
GB8305505 1983-02-28
GB08305505A GB2128984B (en) 1982-05-12 1983-02-28 Diaza-bicyclic compounds

Publications (4)

Publication Number Publication Date
DK194783D0 DK194783D0 (da) 1983-05-02
DK194783A true DK194783A (da) 1983-11-13
DK160612B DK160612B (da) 1991-04-02
DK160612C DK160612C (da) 1991-09-23

Family

ID=26282820

Family Applications (1)

Application Number Title Priority Date Filing Date
DK194783A DK160612C (da) 1982-05-12 1983-05-02 Analogifremgangsmaade til fremstilling af ved begge n-atomer cyclopenta-, cyclohexa- og cyclohepta-annelerede pyrazol- og pyridazinderivater

Country Status (32)

Country Link
US (3) US4512924A (da)
EP (1) EP0094095B1 (da)
KR (1) KR890002106B1 (da)
AR (1) AR240940A1 (da)
AU (1) AU567873B2 (da)
BG (1) BG61123B2 (da)
CA (1) CA1234568A (da)
CS (2) CS249128B2 (da)
CU (1) CU21532A3 (da)
DE (2) DE3317290A1 (da)
DK (1) DK160612C (da)
DO (1) DOP1983004163A (da)
DZ (1) DZ540A1 (da)
ES (6) ES522291A0 (da)
FI (1) FI77244C (da)
FR (1) FR2531956B1 (da)
GB (1) GB2128984B (da)
GR (1) GR77462B (da)
HK (1) HK91692A (da)
HU (3) HU198935B (da)
IE (1) IE56480B1 (da)
IL (1) IL68620A (da)
IT (1) IT1212738B (da)
LU (2) LU84803A1 (da)
MC (1) MC1515A1 (da)
MY (1) MY102889A (da)
NL (2) NL8301640A (da)
NO (1) NO160368C (da)
PT (1) PT76681B (da)
SE (1) SE461792B (da)
SG (1) SG81192G (da)
ZW (1) ZW9883A1 (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3315464A1 (de) * 1983-04-28 1984-10-31 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
US4801721A (en) * 1984-08-16 1989-01-31 Ryan James W Stereospecific synthesis of carboxyalkyl peptides
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
ES8801833A1 (es) * 1985-04-30 1988-02-16 Lilly Co Eli Un procedimiento para la preparacion de un compuesto.
US4940718A (en) * 1985-04-30 1990-07-10 Eli Lilly And Company 7-substituted bicyclic pyrazolidinones, pharmaceutical compositions and use
US4902707A (en) * 1985-04-30 1990-02-20 Eli Lilly And Company Bicyclic pyrazolidinones, compositions and use
US4826992A (en) * 1985-04-30 1989-05-02 Eli Lilly And Company 2,3-(Dihydro) bicyclic pyrazolidinones
ZW11586A1 (en) * 1985-07-01 1987-12-30 Hoffmann La Roche Bicyclic compounds
US4832763A (en) * 1985-10-15 1989-05-23 Westinghouse Electric Corp. Method of stress-relief annealing a magnetic core containing amorphous material
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US5262436A (en) * 1987-03-27 1993-11-16 Schering Corporation Acylamino acid antihypertensives in the treatment of congestive heart failure
US4956490A (en) * 1989-03-09 1990-09-11 Merck & Co., Inc. Process for preparing benzylpyruvic acids and esters
ZA902661B (en) * 1989-04-10 1991-01-30 Schering Corp Mercapto-acyl amino acids
DE3917255A1 (de) * 1989-05-26 1990-11-29 Schopf Masch Verfahren und vorrichtung zum aufnehmen eines flugzeugbugfahrwerks durch einen flugzeugschlepper
US5011938A (en) * 1989-10-02 1991-04-30 Eli Lilly And Company 7-substituted bicyclic pyrazolidinones
US5389610A (en) * 1989-11-21 1995-02-14 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
EP0487453B1 (de) * 1990-11-21 1996-05-22 Ciba-Geigy Ag Silylierte Acylphosphinoxide
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
BR9205752A (pt) * 1991-03-19 1994-11-08 Ciba Geigy Ag Novos compostos herbicidamente, acaricidamente e inseticidamente ativos
TW216770B (da) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5455242A (en) * 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
JPH06107661A (ja) * 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
ATE182892T1 (de) * 1992-05-15 1999-08-15 Merrell Pharma Inc Mercaptoacetylamide von pyridazo(1,2-a>(1,2>- diazepin -derivaten als eukephalinase und ace- inhibitoren
ATE203242T1 (de) * 1992-05-18 2001-08-15 Hoffmann La Roche Asymmetrische hydrierung
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
PT669936E (pt) * 1992-10-30 2001-04-30 Merrell Pharma Inc Derivados de lactama biciclica de mercaptoacetilamida uteis como inibidores de encefalinase e de ace
JPH072859A (ja) * 1993-01-28 1995-01-06 Upjohn Co:The ピラゾール誘導体およびこれを有効成分とする医薬組成物
US5476395A (en) * 1993-03-01 1995-12-19 Methode Electronics, Inc. Planar fuse panel
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
JP3561753B2 (ja) * 1994-02-14 2004-09-02 メレル ファーマスーティカルズ インコーポレーテッド エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規な２−置換インダン−２−メルカプトアセチルアミドジスルフィド誘導体類
PT750631E (pt) * 1994-02-14 2000-07-31 Merrell Pharma Inc Novos derivados de dissulfureto de mercapto-aacetilamido-1,3,4,5-tetra-hidro-benzo¬c)azepin-3-ona uteis como inibidores de encefalinase e ace
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
CA2183313C (en) * 1994-02-14 2001-01-02 Gary A. Flynn Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
JP3596778B2 (ja) * 1994-02-14 2004-12-02 メレル ファーマスーティカルズ インコーポレーテッド エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規なメルカプトアセチルアミドジスルフィド誘導体類
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
PT751783E (pt) * 1994-03-24 2000-05-31 Merrell Pharma Inc Derivados aminoacetilmercapto hipocolesterolemicos antiateroscleroticos e hipotrigliceridemicos
ATE246927T1 (de) * 1994-03-24 2003-08-15 Merrell Pharma Inc Cholesterin senkende mercaptoacetylamiddisulfidderivate
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
FR2777888B1 (fr) * 1998-04-27 2004-07-16 Hoechst Marion Roussel Inc Nouveaux derives de l'acide (3,4,7,8,9,10-hexahydro-6,10- dioxo-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de medicaments
FR2777889B1 (fr) * 1998-04-27 2004-07-09 Hoechst Marion Roussel Inc Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
AU2003200034B2 (en) * 1998-04-27 2006-07-20 Aventis Pharma S.A. New derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-A][1,2]diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds
US6177565B1 (en) * 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
US6559304B1 (en) 1998-08-19 2003-05-06 Vertex Pharmaceuticals Incorporated Method for synthesizing caspase inhibitors
US6703500B2 (en) 1998-08-19 2004-03-09 Vertex Pharmaceuticals, Incorporated Method of preparing bicyclic intermediates from piperazic acid or an ester thereof useful in the manufacture of caspase inhibitors
FR2788276B1 (fr) * 1999-01-12 2001-02-16 Hoechst Marion Roussel Inc NOUVEAU PROCEDE DE PREPARATION DE COMPOSES BICYCLIQUES ET L'APPLICATION DE CE PROCEDE COMME ETAPE INTERMEDIAIRE POUR LA PREPARATION D'UN COMPOSE INHIBITEUR DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1-BETA (ice)
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
ATE532070T1 (de) 2000-12-14 2011-11-15 Brigham & Womens Hospital Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US20040110241A1 (en) * 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP1603916A1 (en) * 2003-03-06 2005-12-14 Ranbaxy Laboratories, Ltd. Enantiomerically pure cilazapril, process for preparation
WO2005003134A1 (en) * 2003-07-07 2005-01-13 Hetero Drugs Limited A novel process for the preparation of cilazapril
DK2384753T3 (da) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoinderivater som inhibitorer for cellenekrose
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2005122682A2 (en) 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Process for the preparation of esters of piperazic acid
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20070281000A1 (en) * 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
DE602006000402T8 (de) 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US20080008751A1 (en) * 2006-07-10 2008-01-10 Michael Fox Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2221299A3 (en) 2009-02-11 2010-11-03 Dr. Reddy's Laboratories Ltd. Preparation of cilazapril intermediates
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
TWI621420B (zh) 2010-04-08 2018-04-21 病童醫院 遠距缺血處理於創傷性傷害的用途
WO2012049646A1 (en) 2010-10-12 2012-04-19 Ranbaxy Laboratories Limited Process for the preparation of an intermediate of cilazapril
EP2537534B1 (en) 2011-06-22 2014-12-17 Hexal AG Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use.
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
CN104640856B (zh) 2012-05-11 2017-09-15 复位治疗公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IL60617A0 (en) * 1979-07-23 1980-09-16 Sparamedica Ag Triazolopyridazine derivative,their preparation and pharmaceutical compositions containing them
EP0025941B1 (de) * 1979-09-19 1983-05-04 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyridazopyridazinderivate, Verfahren zu deren Herstellung und Arzneimittel enthaltend solche Pyridazopyridazinderivate
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
EP0047620B1 (en) * 1980-09-10 1985-03-13 Beecham Group Plc Aryl diazabicyclyl amides, a process for their preparation and use
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds

Also Published As

Publication number Publication date
ES528627A0 (es) 1985-11-16
DK160612B (da) 1991-04-02
US4512924A (en) 1985-04-23
CA1234568A (en) 1988-03-29
ES8505173A1 (es) 1985-05-16
ES528630A0 (es) 1986-06-16
SG81192G (en) 1993-01-29
DE3317290A1 (de) 1983-11-17
FI831661A0 (fi) 1983-05-12
US4658024A (en) 1987-04-14
AR240940A1 (es) 1991-03-27
FI77244C (fi) 1989-02-10
MC1515A1 (fr) 1984-02-10
NO831675L (no) 1983-11-14
NL8301640A (nl) 1983-12-01
NL930055I1 (nl) 1993-09-01
FI77244B (fi) 1988-10-31
KR840004754A (ko) 1984-10-24
GB8305505D0 (en) 1983-03-30
CS249128B2 (en) 1987-03-12
PT76681B (en) 1986-05-20
IE56480B1 (en) 1991-08-14
ES8407049A1 (es) 1984-08-16
IE831084L (en) 1983-11-12
BG61123B2 (bg) 1996-11-29
FR2531956B1 (fr) 1987-02-20
AR240940A2 (es) 1991-03-27
HU198935B (en) 1989-12-28
EP0094095B1 (de) 1990-09-19
IT8321000A0 (it) 1983-05-09
NO160368B (no) 1989-01-02
HU195965B (en) 1988-08-29
SE8302716D0 (sv) 1983-05-11
ES554935A0 (es) 1987-11-01
US4772701A (en) 1988-09-20
DE3381884D1 (de) 1990-10-25
LU88299I2 (fr) 1994-09-09
PT76681A (en) 1983-06-01
AU567873B2 (en) 1987-12-10
MY102889A (en) 1993-03-31
HU199842B (en) 1990-03-28
HK91692A (en) 1992-11-27
CS402191A3 (en) 1992-10-14
ES528628A0 (es) 1987-07-16
ES8800170A1 (es) 1987-11-01
GB2128984B (en) 1985-05-22
DK194783D0 (da) 1983-05-02
GB2128984A (en) 1984-05-10
IL68620A (en) 1987-11-30
EP0094095A3 (en) 1984-11-21
NO160368C (no) 1989-04-12
LU84803A1 (fr) 1985-03-21
FR2531956A1 (fr) 1984-02-24
IT1212738B (it) 1989-11-30
EP0094095A2 (de) 1983-11-16
FI831661L (fi) 1983-11-13
DZ540A1 (fr) 2004-09-13
ES528625A0 (es) 1985-05-16
DK160612C (da) 1991-09-23
GR77462B (da) 1984-09-24
ES8601994A1 (es) 1985-11-16
IL68620A0 (en) 1983-09-30
ES8706672A1 (es) 1987-07-16
SE8302716L (sv) 1983-11-13
NL930055I2 (nl) 1993-10-01
ES522291A0 (es) 1984-08-16
SE461792B (sv) 1990-03-26
DOP1983004163A (es) 1988-09-20
ZW9883A1 (en) 1984-11-21
CU21532A3 (en) 1987-06-09
AU1436483A (en) 1983-11-17
KR890002106B1 (ko) 1989-06-19
ES8607970A1 (es) 1986-06-16

Similar Documents

Publication Publication Date Title
DK161770C (da) Analogifremgangsmaade til fremstilling af cyklobutylaminderivater eller farmaceutisk acceptable salte deraf
DK145339C (da) Analogifremgangsmaade til fremstilling af 4-amino-5-hexensyre eller farmaceutisk acceptable salte deraf
DK156434C (da) Analogifremgangsmaade til fremstilling af sulfonylurinstoffer eller deres fysiologisk acceptable salte
DK245883D0 (da) Fremgangsmade til fremstilling af en eller flere af de rene enkeltfaktorer 1,2,3,4 og 5 af teichomycin a2 eller farmaceutisk acceptable salte deraf
DK152114C (da) Analogifremgangsmaade til fremstilling af propenylaminer eller farmaceutisk acceptable salte deraf
DK148260C (da) Analogifremgangsmaade til fremstilling af 1,3,8-trisubstituerede xantinderivater eller salte deraf
DK161968C (da) Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf
DK157022C (da) Analogifremgangsmaade til fremstilling af 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido oe1,2-aaapyrimidinderivater eller farmaceutisk acceptable salte, hydrater, stereoisomere, optisk aktive isomere, geometriske isomere og tautomere deraf
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
DK146160C (da) Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-4-oxo-4h-pyrimido(2,1-b)benzothiazol-3-carboxamider eller farmaceutisk acceptable salte deraf med baser
DK143183C (da) Analogifremgangsmaade til fremstilling af 1h-pyrazolo(3,4-b)pyridiner eller fysiologisk acceptable salte deraf
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK161699C (da) Analogifremgangsmaade til fremstilling af 4-aryl-4-piperidincarbinoler eller farmaceutisk acceptable salte deraf
DK155670C (da) Analogifremgangsmaade til fremstilling af sesquiterpenderivater eller farmaceutisk acceptable salte deraf
DK145263C (da) Analogifremgangsmaade til fremstilling af imidazothiaziner eller farmaceutisk acceptable salte deraf
DK151805C (da) Analogifremgangsmaade til fremstilling af 20,21-di-nor-eburnameninderivater eller farmaceutisk acceptable additionssalte deraf
DK149093C (da) Analogifremgangsmaade til fremstilling af pentapeptidderivater eller farmaceutisk acceptable salte deraf
DK152754C (da) Analogifremgangsmaade til fremstilling af 1-acyl-8-(3-amino-2-hydroxypropoxy)-1,2,3,4-tetrahydroquinoliner eller farmaceutisk acceptable syreadditionssalte deraf
DK150521C (da) Analogifremgangsmaade til fremstilling af n2-arylsulfonyl-l-argininamider eller farmaceutisk acceptable salte deraf
DK157021C (da) Analogifremgangsmaade til fremstilling af 2,3-polymethylen-4-oxo-4h-pyrido- eller -azepinooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf
DK165983C (da) Fremgangsmaade til fremstilling af phosphorholdige antibiotiske forbindelser betegnet cl 1565-a, cl 1565-b og cl 1565-t eller farmaceutisk acceptable salte deraf
DK157081C (da) Analogifremgangsmaade til fremstilling af 3-oe(s)-1'-phenylethylaminoaapropylaminobleomycin eller ugiftige salte deraf
DK149823C (da) Fremgangsmaade til fremstilling af kijanimicin eller farmaceutisk acceptable salte heraf
DK150481C (da) Analogifremgangsmaade til fremstilling af 3',4'-dihydro-spiro-(imidazolidin-4,1'-(2'h)-naphthalen)-5-on eller farmaceutisk acceptable syreadditionssalte deraf
DK148826C (da) Analogifremgangsmaade til fremstilling af oxadiazolopyrimidinderivater eller salte deraf med baser og pyrimidinderivat til anvendelse som mellemprodukt ved denne fremgangsmaade

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1993 00045, 930629

CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1993 00045, 930629

PUP Patent expired